Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
Portfolio Pulse from Benzinga Newsdesk
Adaptimmune and Galapagos have entered a clinical collaboration to license next-generation TCR T-cell therapy for cancer using a decentralized manufacturing platform. The collaboration will focus on a clinical proof-of-concept trial for uza-cel in head & neck cancer. Adaptimmune will receive initial payments of $100 million, with potential additional payments up to $565 million.
May 30, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptimmune has entered a collaboration with Galapagos to license next-gen TCR T-cell therapy for cancer, receiving initial payments of $100 million and potential additional payments up to $565 million.
The collaboration with Galapagos and the significant financial inflow from the deal are likely to positively impact Adaptimmune's stock in the short term. The potential for additional milestone payments and royalties further strengthens this outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Galapagos has entered a collaboration with Adaptimmune to license next-gen TCR T-cell therapy for cancer, focusing on a clinical proof-of-concept trial for uza-cel in head & neck cancer.
The collaboration with Adaptimmune and the potential to exclusively license uza-cel for global development and commercialization are likely to positively impact Galapagos' stock in the short term. The decentralized manufacturing platform's promising initial data further supports this outlook.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100